319 related articles for article (PubMed ID: 25663202)
41. Radiotherapy with concurrent or sequential temozolomide in elderly patients with glioblastoma multiforme.
Hashem SA; Salem A; Al-Rashdan A; Ezam N; Nour A; Alsharbaji A; Rejeeth C; Mohamad I; Sughayer M; Elyan M; Al-Hussaini M; Addasi A; Almousa A
J Med Imaging Radiat Oncol; 2012 Apr; 56(2):204-10. PubMed ID: 22498195
[TBL] [Abstract][Full Text] [Related]
42. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide.
Donato V; Papaleo A; Castrichino A; Banelli E; Giangaspero F; Salvati M; Delfini R
Tumori; 2007; 93(3):248-56. PubMed ID: 17679459
[TBL] [Abstract][Full Text] [Related]
43. Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients.
Behm T; Horowski A; Schneider S; Bock HC; Mielke D; Rohde V; Stockhammer F
Clin Neurol Neurosurg; 2013 Oct; 115(10):2142-6. PubMed ID: 23993314
[TBL] [Abstract][Full Text] [Related]
44. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
[TBL] [Abstract][Full Text] [Related]
45. Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.
Herrlinger U; Rieger J; Koch D; Loeser S; Blaschke B; Kortmann RD; Steinbach JP; Hundsberger T; Wick W; Meyermann R; Tan TC; Sommer C; Bamberg M; Reifenberger G; Weller M
J Clin Oncol; 2006 Sep; 24(27):4412-7. PubMed ID: 16983109
[TBL] [Abstract][Full Text] [Related]
46. Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme.
Lee JH; Jung TY; Jung S; Kim IY; Jang WY; Moon KS; Jeong EH
J Clin Neurosci; 2013 Apr; 20(4):503-8. PubMed ID: 23313530
[TBL] [Abstract][Full Text] [Related]
47. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Perry JR; Laperriere N; O'Callaghan CJ; Brandes AA; Menten J; Phillips C; Fay M; Nishikawa R; Cairncross JG; Roa W; Osoba D; Rossiter JP; Sahgal A; Hirte H; Laigle-Donadey F; Franceschi E; Chinot O; Golfinopoulos V; Fariselli L; Wick A; Feuvret L; Back M; Tills M; Winch C; Baumert BG; Wick W; Ding K; Mason WP;
N Engl J Med; 2017 Mar; 376(11):1027-1037. PubMed ID: 28296618
[TBL] [Abstract][Full Text] [Related]
48. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
[TBL] [Abstract][Full Text] [Related]
49. Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
Wick W; Gorlia T; Bady P; Platten M; van den Bent MJ; Taphoorn MJ; Steuve J; Brandes AA; Hamou MF; Wick A; Kosch M; Weller M; Stupp R; Roth P; Golfinopoulos V; Frenel JS; Campone M; Ricard D; Marosi C; Villa S; Weyerbrock A; Hopkins K; Homicsko K; Lhermitte B; Pesce G; Hegi ME
Clin Cancer Res; 2016 Oct; 22(19):4797-4806. PubMed ID: 27143690
[TBL] [Abstract][Full Text] [Related]
50. The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
McDonald KL; Rapkins RW; Olivier J; Zhao L; Nozue K; Lu D; Tiwari S; Kuroiwa-Trzmielina J; Brewer J; Wheeler HR; Hitchins MP
Eur J Cancer; 2013 Jan; 49(2):360-8. PubMed ID: 22975219
[TBL] [Abstract][Full Text] [Related]
51. Prognostic significance of concomitant radiotherapy in newly diagnosed glioblastoma multiforme: a multivariate analysis of 116 patients.
Okumus NO; Gursel B; Meydan D; Ozdemir O; Odabas E; Gonullu G
Ann Saudi Med; 2012; 32(3):250-5. PubMed ID: 22588435
[TBL] [Abstract][Full Text] [Related]
52. Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Kim C; Kim HS; Shim WH; Choi CG; Kim SJ; Kim JH
Radiology; 2017 Jan; 282(1):212-221. PubMed ID: 27428890
[TBL] [Abstract][Full Text] [Related]
53. [Temozolomide in patients with a glioblastoma multiforme: new developments].
Bromberg JE; Postma TJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
[TBL] [Abstract][Full Text] [Related]
54. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
[TBL] [Abstract][Full Text] [Related]
55. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
Mirimanoff RO; Gorlia T; Mason W; Van den Bent MJ; Kortmann RD; Fisher B; Reni M; Brandes AA; Curschmann J; Villa S; Cairncross G; Allgeier A; Lacombe D; Stupp R
J Clin Oncol; 2006 Jun; 24(16):2563-9. PubMed ID: 16735709
[TBL] [Abstract][Full Text] [Related]
56. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Motomura K; Natsume A; Kishida Y; Higashi H; Kondo Y; Nakasu Y; Abe T; Namba H; Wakai K; Wakabayashi T
Cancer; 2011 Apr; 117(8):1721-30. PubMed ID: 21472719
[TBL] [Abstract][Full Text] [Related]
57. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Rapkins RW; Wang F; Nguyen HN; Cloughesy TF; Lai A; Ha W; Nowak AK; Hitchins MP; McDonald KL
Neuro Oncol; 2015 Dec; 17(12):1589-98. PubMed ID: 25910840
[TBL] [Abstract][Full Text] [Related]
58. Is a reduction of radiation dose feasible in patients affected by glioblastoma undergoing radio-chemotherapy according to MGMT promoter methylation status without jeopardizing survival?
Tini P; Nardone V; Pastina P; Marampon F; Sebaste L; Cerase A; Tombolini V; Pirtoli L; Mazzei MA
Clin Neurol Neurosurg; 2019 Sep; 184():105445. PubMed ID: 31325903
[TBL] [Abstract][Full Text] [Related]
59. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H
J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115
[TBL] [Abstract][Full Text] [Related]
60. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
Weiler M; Hartmann C; Wiewrodt D; Herrlinger U; Gorlia T; Bähr O; Meyermann R; Bamberg M; Tatagiba M; von Deimling A; Weller M; Wick W
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):670-6. PubMed ID: 19836157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
